| Raltegravir Potassium |
Tablet |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Ramelteon |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Ramipril |
Capsule |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Ramipril |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Ranitidine HCl |
Tablet |
|
|
Develop a dissolution method |
|
|
2024/01/03 |
| Ranitidine HCl |
Capsule |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Ranitidine HCl |
Tablet (Effervescent) |
|
|
Develop a dissolution method |
|
|
2010/04/08 |
| Ranolazine |
Tablet (Extended Release) |
|
|
Develop a dissolution method |
|
|
2019/02/07 |
| Ranolazine |
Granules (Extended Release) |
II (Paddle) |
50 |
0.1 N HCl |
900 |
0.5, 1, 2, 3, 4, 6 and 8 hours |
2022/07/07 |
| Rasagiline Mesylate |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Regorafenib |
Tablet |
II (Paddle) |
75 |
Acetate Buffer pH 4.5 with 0.1% Sodium Dodecyl Sulfate (SDS) |
900 |
10, 15, 20, 30 and 45 |
2015/06/25 |
| Relugolix |
Tablet |
II (Paddle) |
50 |
50 mM Citrate Buffer, pH 5.5 |
900 |
5, 10, 15, 20 and 30 |
2022/07/07 |
| Repaglinide |
Tablet |
|
|
Refer to USP |
|
|
2007/07/25 |
| Repotrectinib |
Capsule |
II (Paddle) with sinker |
75 |
50 mM Sodium Phosphate Buffer, pH 6.8, w/ 0.075% SLS |
900 |
5, 10, 15, 30, 45, 60 and 75 |
2025/06/23 |
| Resmetirom |
Tablet |
|
|
Develop a dissolution method |
|
|
2024/09/03 |
| Revumenib Citrate |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2026/01/28 |
| Ribavirin |
Tablet |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Ribavirin |
Capsule |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Ribociclib |
Tablet |
II (Paddle) |
50 |
0.01N HCl (degassed) |
900 |
10, 20, 30, 45 and 60 |
2022/05/12 |
| Rifabutin |
Capsule |
|
|
Refer to USP |
|
|
2009/12/15 |